Skip to Content

Becton Dickinson & Co

BDX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$888.00PtwywtHcwxxdmk

BD Continues Growing Even as COVID-19 Testing Pulls Back

We are maintaining our $306 fair value estimate for narrow-moat Becton, Dickinson as we update our model following fiscal third-quarter results and updated full-year guidance. BD increased its revenue forecast to $18.75 billion-$18.83 billion with higher COVID-only testing revenue. Including COVID-only testing revenue, the firm expects fiscal 2022 revenue to be down approximately 1.6%-2% from fiscal 2021 levels. We anticipate that much of the remaining COVID-focused production equipment will be quickly repurposed as the demand for COVID tests diminishes to push overall growth going forward.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BDX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center